| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 13, 2001
Revised on January 25, 2002
Accepted on January 25, 2002
From the Department of Physiology, School of Medicine (L.G.-S., S.L.-O., M.R.-P.), and Nephrology Section (D.R.-P.), Hospital Príncipe de Asturias, Alcalá University, and IRSIN, Madrid, Spain.
* To whom correspondence should be addressed. E-mail: drodriguez{at}hupa.insalud.es.
Endothelial dysfunction, considered as a defective vascular dilatation after certain stimuli, is characteristic of different pathological conditions, such as hypertension, atherosclerosis, or diabetes. A decreased synthesis or an increased degradation of nitric oxide (NO) has been postulated as the mechanism responsible for this alteration. The present experiments were designed to test the hypothesis that the presence of an abnormal extracellular matrix in vessel walls could be responsible for the decreased NO synthesis observed in these pathological conditions. Experiments were performed in cultured human umbilical vein endothelial cells (HUVECs) grown on type IV (Col. IV) or type I (Col. I) collagen. Cells seeded on Col. I showed decreased nitrite synthesis, nitric oxide synthase activity, eNOS protein content, and eNOS mRNA expression when compared with cells grown on Col. IV. Moreover, cells grown on Col. I failed to respond to glucose oxidase activation of the eNOS system. In both cases, the changes in the eNOS mRNA expression seemed to depend on the modulation of eNOS promoter activity. The downregulation of eNOS induced by Col. I was blocked by D6Y, a peptide that interferes with the Col. I--dependent signals through integrins, as well as by specific anti-integrin antibodies. Moreover, a decreased activation of integrin-linked kinase (ILK) may explain the effects observed in Col. I--cultured cells because the activity of this kinase was decreased in these cells and ILK modulation prevented the Col. I--induced changes in HUVECs. Taken together, these findings may contribute to explaining the basis of endothelial dysfunction in some vascular diseases.
This article has been cited by other articles:
![]() |
C. S. Packer Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: Implications in metabolic syndrome Cardiovasc Res, February 1, 2006; 69(2): 302 - 303. [Full Text] [PDF] |
||||
![]() |
M. L. Diez-Marques, M. P. Ruiz-Torres, M. Griera, S. Lopez-Ongil, M. Saura, D. Rodriguez-Puyol, and M. Rodriguez-Puyol Arg-Gly-Asp (RGD)-containing peptides increase soluble guanylate cyclase in contractile cells Cardiovasc Res, February 1, 2006; 69(2): 359 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. De Frutos, M. Saura, M. Griera, F. J. Rivero-Vilches, C. Zaragoza, D. Rodriguez-Puyol, and M. Rodriguez-Puyol Differential Regulation of Soluble Guanylyl Cyclase Expression and Signaling by Collagens: Involvement of Integrin-Linked Kinase J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2626 - 2635. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Rivero-Vilches, S De Frutos, M Saura, D Rodriguez-Puyol, and M Rodriguez-Puyol Differential relaxing responses to particulate or soluble guanylyl cyclase activation on endothelial cells: a mechanism dependent on PKG-I{alpha} activation by NO/cGMP Am J Physiol Cell Physiol, October 1, 2003; 285(4): C891 - C898. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |